We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Objective: There is clear evidence of a genetic component in major depression, and several studies indicate that neuropeptide Y (NPY) could play an important role in the pathophysiology of the disease. A well-known polymorphism encoding the substitution of leucine to proline in the signal peptide sequence of NPY (Leu7Pro variation) was previously found to protect against depression. Our study aimed at replicating this association in a large Danish population with major depression.
Method: Leu7Pro was studied in a sample of depressed patients and ethnically matched controls, as well as psychiatric disease controls with schizophrenia. Possible functional consequences of Leu7Pro were explored in vitro.
Results: In contrast to previous studies, Pro7 appeared to be a risk allele for depression, being significantly more frequent in the depression sample (5.5%, n = 593; p = 0.009; odds ratio, OR: 1.46) as compared to ethnically matched controls (3.8%, n = 2912), while schizophrenia patients (4.1%, n = 503) did not differ. In vitro, the Pro7 substitution appeared to be associated with reduced levels of NPY without affecting its mRNA level.
Conclusion: The Leu7Pro variation may increase the risk of major depression, possibly by affecting the biosynthesis of NPY.
This chapter reviews the genetics of sleep and its most widely used correlate, the electroencephalogram (EEG), in mice and humans. Monozygotic (MZ) and dizygotic (DZ) studies allow measurement of genetic and environmental contributions to a trait. Reverse genetic approaches involve isolation of candidate genes, use of transgenic models, and phenotypic analysis of mutant animals. The first quantitative trait locus (QTL) mapping study for sleep amounts identified several genomic regions associated with the amount of rapid eye movement (REM) sleep. For the identification of genes involved in sleep, large-scale analysis of gene expression by microarrays has been performed in rats and mice. Microarray studies allow better understanding of how gene expression changes as a function of duration of wakefulness. A mutagenesis screen in mice is underway and might turn out to be successful in finding major genes regulating sleep duration as well as EEG.
This chapter presents results from studies showing strong evidence for pronounced heritability of waking and rapid eye movement (REM) and non-REM sleep electroencephalographic (EEG) activity. Genes regulate the expression and function of the neurobiological systems that modulate sleep and wakefulness. The most commonly employed method for identifying genes involved in some aspect of physiological or behavioral regulation is the candidate gene approach. In this approach, individuals with genetic polymorphisms thought to be involved in sleep-wake regulation or neurobehavioral vulnerability to sleep loss are subjected to sleep loss in the laboratory, and neurobehavioral measures are assessed throughout. The chapter determines whether functional polymorphisms of the catechol-O-methyltransferase (COMT) gene moderate responsivity to other psychostimulants that also act via dopaminergic signaling. Genetic variations also appear to control individual responsivity to stimulants. Evidence indicates that the COMT Val158Met polymorphism controls individual responsivity to the stimulant modafinil during sleep loss.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.